Analyst consensus rating
Galectin Therapeutics Analyst Rating: Strong Buy
Direct answer
Galectin Therapeutics's consensus rating is Strong Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.00.
Forecast evidence checked November 18, 2026.
Get free Galectin Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.91
- Average price target
- $11.00
- High price target
- $11.00
- Low price target
- $11.00
- Low target gap
- +278%
- Target upside
- +278%
- High target gap
- +278%
- Target range width
- 0%
- Consensus rating
- Strong Buy
- Analysts
- 1
- Evidence date
- November 18, 2026
- Valid through
- November 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Galectin Therapeutics?
Galectin Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $11.00.
How far are Galectin Therapeutics's low and high targets from the recorded price?
The low target implies +278%, while the high target implies +278%.
How many analysts are included in Galectin Therapeutics's consensus?
The verified consensus includes 1 analysts.
How is Galectin Therapeutics's target upside or downside calculated?
The average target of $11.00 is divided by the recorded price of $2.91, then one is subtracted to produce +278%. This does not guarantee a future return.
When was Galectin Therapeutics's analyst forecast verified?
The data was verified on 2026-11-18. The dataset is valid through 2026-11-25.